Efficacy of Dupilumab in the treatment of severe atopic dermatitis in children
10.3760/cma.j.cn101070-20211125-01395
- VernacularTitle:度普利尤单抗治疗儿童重度特应性皮炎疗效分析
- Author:
Yuhui HAN
1
;
Changshan LIU
;
Yifan LI
;
Shuhui HUANG
Author Information
1. 天津医科大学第二医院儿科，天津 300211
- Keywords:
Atopic dermatitis;
Dupilumab;
Child;
Efficacy
- From:
Chinese Journal of Applied Clinical Pediatrics
2022;37(18):1423-1425
- CountryChina
- Language:Chinese
-
Abstract:
This clinical data of 3 cases of severe atopic dermatitis (AD) who had no remission after taking to-pical glucocorticoids and antihistamines were collected retrospectively.The patients were treated with Dupilumab in the Department of Pediatrics, the Second Hospital of Tianjin Medical University from April to October 2021.All 3 cases developed eczema-like rashes with strong itching and sleep disturbance within the first year after their birth.The children′ quality of life was seriously impaired.All the cases were combined with allergic rhinitis, 2 cases of whom were simultaneously complicated with bronchial asthma.After 14-18 weeks of treatment, the rash, pruritic symptoms and quality of life were significantly improved.Meanwhile, rhinitis symptoms were reduced, asthma control scores and lung function were improved to varying degrees.No serious adverse reactions occurred during the injection period.
